Generic Name: lenvatinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Eisai

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

General Info

Lenvima is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, FGFR, KIT and RET, that play a role in cell growth and development of blood vessels that feed tumors.

Clinical trials showed that Lenvima slows disease progression in people with locally recurrent or metastatic thyroid cancer and previously treated kidney cancer. The Phase III REFLECT trial showed that Lenvima as first-line therapy improved progression-free survival in people with liver cancer. It was first approved in 2015.


Dosing Info:

Lenvima is taken as a once-daily capsule.

Side Effects

Common side effects include fatigue, diarrhea, nausea, loss of appetite, weight loss, high blood pressure, muscle or joint pain, skin rash, mouth sores and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include severe hypertension, severe bleeding (hemorrhage), heart problems, blood clots in arteries, thyroid problems, liver toxicity and kidney toxicity with protein loss in the urine and slow wound healing. Lenvima may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 15, 2018